Sonoma Common Stock Total Equity vs Non Current Assets Total Analysis

SNOA Stock  USD 2.81  0.02  0.72%   
Sonoma Pharmaceuticals financial indicator trend analysis is much more than just breaking down Sonoma Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonoma Pharmaceuticals is a good investment. Please check the relationship between Sonoma Pharmaceuticals Common Stock Total Equity and its Non Current Assets Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

Common Stock Total Equity vs Non Current Assets Total

Common Stock Total Equity vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonoma Pharmaceuticals Common Stock Total Equity account and Non Current Assets Total. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Sonoma Pharmaceuticals' Common Stock Total Equity and Non Current Assets Total is -0.09. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Sonoma Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Sonoma Pharmaceuticals' Common Stock Total Equity and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Sonoma Pharmaceuticals are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Common Stock Total Equity i.e., Sonoma Pharmaceuticals' Common Stock Total Equity and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

-0.09
Relationship DirectionNegative 
Relationship StrengthInsignificant

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from Sonoma Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 3.5 M, whereas Discontinued Operations is forecasted to decline to about 568.6 K.
 2021 2022 2023 2024 (projected)
Gross Profit4.0M4.5M4.7M5.1M
Total Revenue12.6M13.3M12.7M11.3M

Sonoma Pharmaceuticals fundamental ratios Correlations

0.86-0.730.740.740.20.880.320.690.22-0.490.060.06-0.34-0.19-0.570.210.410.570.25-0.68-0.040.450.270.0-0.53
0.86-0.860.790.790.320.760.310.41-0.3-0.720.29-0.23-0.07-0.33-0.260.210.360.640.11-0.39-0.460.390.0-0.16-0.79
-0.73-0.86-0.97-0.97-0.06-0.74-0.17-0.220.280.52-0.30.20.010.090.03-0.07-0.14-0.520.190.270.42-0.140.140.20.58
0.740.79-0.971.00.030.790.180.27-0.14-0.330.21-0.17-0.06-0.07-0.120.130.050.55-0.16-0.37-0.260.12-0.09-0.24-0.43
0.740.79-0.971.00.030.790.180.27-0.14-0.330.21-0.17-0.06-0.07-0.120.130.050.55-0.16-0.37-0.260.12-0.09-0.24-0.43
0.20.32-0.060.030.030.280.190.36-0.24-0.230.28-0.140.03-0.51-0.290.55-0.130.450.82-0.25-0.380.45-0.23-0.14-0.28
0.880.76-0.740.790.790.280.490.740.18-0.31-0.16-0.2-0.32-0.44-0.640.36-0.080.710.3-0.660.070.610.350.08-0.31
0.320.31-0.170.180.180.190.490.260.03-0.16-0.55-0.310.11-0.56-0.410.15-0.220.670.120.00.310.690.610.630.06
0.690.41-0.220.270.270.360.740.260.5-0.19-0.29-0.08-0.7-0.46-0.910.31-0.020.390.62-0.90.310.690.480.14-0.16
0.22-0.30.28-0.14-0.14-0.240.180.030.50.46-0.450.56-0.490.28-0.56-0.010.08-0.150.25-0.510.810.10.520.310.54
-0.49-0.720.52-0.33-0.33-0.23-0.31-0.16-0.190.46-0.30.20.140.210.090.17-0.46-0.160.00.110.56-0.25-0.01-0.060.89
0.060.29-0.30.210.210.28-0.16-0.55-0.29-0.45-0.30.30.180.380.51-0.030.430.00.020.09-0.84-0.37-0.87-0.69-0.49
0.06-0.230.2-0.17-0.17-0.14-0.2-0.31-0.080.560.20.30.020.750.11-0.030.51-0.310.09-0.010.13-0.33-0.110.00.23
-0.34-0.070.01-0.06-0.060.03-0.320.11-0.7-0.490.140.180.020.030.680.25-0.020.12-0.290.81-0.32-0.25-0.260.050.07
-0.19-0.330.09-0.07-0.07-0.51-0.44-0.56-0.460.280.210.380.750.030.48-0.450.43-0.58-0.430.210.01-0.77-0.38-0.210.22
-0.57-0.260.03-0.12-0.12-0.29-0.64-0.41-0.91-0.560.090.510.110.680.48-0.270.08-0.32-0.590.83-0.52-0.64-0.67-0.250.02
0.210.21-0.070.130.130.550.360.150.31-0.010.17-0.03-0.030.25-0.45-0.27-0.260.460.54-0.17-0.080.390.07-0.140.0
0.410.36-0.140.050.05-0.13-0.08-0.22-0.020.08-0.460.430.51-0.020.430.08-0.26-0.15-0.09-0.09-0.24-0.22-0.11-0.13-0.52
0.570.64-0.520.550.550.450.710.670.39-0.15-0.160.0-0.310.12-0.58-0.320.46-0.150.29-0.25-0.140.720.1-0.03-0.21
0.250.110.19-0.16-0.160.820.30.120.620.250.00.020.09-0.29-0.43-0.590.54-0.090.29-0.510.050.530.06-0.03-0.04
-0.68-0.390.27-0.37-0.37-0.25-0.660.0-0.9-0.510.110.09-0.010.810.210.83-0.17-0.09-0.25-0.51-0.25-0.38-0.260.170.18
-0.04-0.460.42-0.26-0.26-0.380.070.310.310.810.56-0.840.13-0.320.01-0.52-0.08-0.24-0.140.05-0.250.140.740.520.69
0.450.39-0.140.120.120.450.610.690.690.1-0.25-0.37-0.33-0.25-0.77-0.640.39-0.220.720.53-0.380.140.50.36-0.12
0.270.00.14-0.09-0.09-0.230.350.610.480.52-0.01-0.87-0.11-0.26-0.38-0.670.07-0.110.10.06-0.260.740.50.740.2
0.0-0.160.2-0.24-0.24-0.140.080.630.140.31-0.06-0.690.00.05-0.21-0.25-0.14-0.13-0.03-0.030.170.520.360.740.29
-0.53-0.790.58-0.43-0.43-0.28-0.310.06-0.160.540.89-0.490.230.070.220.020.0-0.52-0.21-0.040.180.69-0.120.20.29
Click cells to compare fundamentals

Sonoma Pharmaceuticals Account Relationship Matchups

Sonoma Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets14.6M15.0M18.8M16.2M14.7M15.3M
Total Stockholder Equity8.7M5.4M8.7M8.0M6.1M8.7M
Net Debt(2.2M)(1.5M)(6.0M)(3.0M)(2.5M)(2.6M)
Cash3.7M4.2M7.4M3.8M3.1M5.3M
Cash And Short Term Investments3.7M4.2M7.4M3.8M3.1M5.3M
Common Stock Shares Outstanding1.5M99.8K132.7K169.7K454.5K262.8K
Liabilities And Stockholders Equity14.6M15.0M18.8M16.2M14.7M15.3M
Total Current Assets12.4M13.0M16.4M13.8M12.5M12.6M
Other Assets850K875K1.5M1.5M1.8M1.8M
Other Stockholder Equity186.6M189.2M197.4M200.9M203.2M148.5M
Total Liab5.9M9.6M10.1M8.3M8.6M6.9M
Short Long Term Debt Total1.5M2.7M1.4M849K608K1.2M
Other Current Liab1.8M(2.6M)(2.0M)(2.5M)(2.8M)(2.7M)
Total Current Liabilities4.9M4.1M5.8M3.7M3.7M3.7M
Property Plant And Equipment Net1.3M1.1M879K906K651K958.7K
Current Deferred Revenue273K319K1.3M160K478K673.3K
Retained Earnings(172.2M)(179.3M)(184.4M)(189.5M)(194.3M)(204.1M)
Accounts Payable2.1M1.8M1.6M841K607K1.1M
Non Current Assets Total2.2M2.0M2.4M2.4M2.2M2.9M
Non Currrent Assets Other850K875K707K578K396K584.7K
Net Receivables5.4M2.8M2.4M2.6M2.9M2.3M
Non Current Liabilities Total991K5.5M4.3M4.5M4.9M5.1M
Inventory2.2M2.5M2.7M2.9M2.7M1.7M
Other Current Assets428K3.4M4.0M4.5M3.8M4.0M
Property Plant And Equipment Gross1.3M1.1M2.6M2.9M3.0M1.7M
Accumulated Other Comprehensive Income(5.6M)(4.6M)(4.3M)(3.4M)(2.7M)(2.9M)
Short Term Debt732K1.1M1.1M943K719K781.0K
Property Plant Equipment365K1.1M879K906K815.4K906.4K
Other Liab245K3.7M4.0M4.4M5.0M5.3M
Retained Earnings Total Equity(157.4M)(169.2M)(172.2M)(179.3M)(161.3M)(169.4M)
Deferred Long Term Liab443K356K245K229K263.4K382.5K
Net Tangible Assets8.7M5.4M8.7M8.0M7.2M9.0M
Capital Surpluse176.7M184.1M186.6M189.2M217.6M189.6M
Short Long Term Debt481K596K808K431K323K366.2K
Capital Lease Obligations997K769K559K418K285K478.6K
Net Invested Capital9.2M7.3M9.5M8.4M6.5M7.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
20.967
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.20)
Return On Equity
(0.75)
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.